These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12114415)

  • 61. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
    Trump DL; Tutsch KD; Koeller JM; Tormey DC
    Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.
    Ramaswamy B; Mrozek E; Kuebler JP; Bekaii-Saab T; Kraut EH
    Invest New Drugs; 2011 Apr; 29(2):347-51. PubMed ID: 19844661
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist.
    Clive S; Webb DJ; MacLellan A; Young A; Byrne B; Robson L; Smyth JF; Jodrell DI
    Clin Cancer Res; 2001 Oct; 7(10):3071-8. PubMed ID: 11595697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
    Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study.
    Spriggs DR; Robbins G; Takvorian T; Kufe DW
    Cancer Res; 1985 Aug; 45(8):3932-6. PubMed ID: 4016760
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
    Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
    Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study.
    Bastasch M; Panella TJ; Kretzschmer SL; Graham D; Mayo M; Williamson S
    Invest New Drugs; 2002 Aug; 20(3):339-42. PubMed ID: 12201497
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
    Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
    Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
    Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
    Berg SL; Savarese DM; Balis FM; Denicoff AM; Hillig M; O'Shaughnessy JA; Poplack DG; Cowan KH
    Cancer Res; 1993 Jun; 53(11):2587-90. PubMed ID: 7684320
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I evaluation of IMPY in a twice weekly schedule.
    Haas CD; Joseph U; Belt RJ; Hoogstraten B
    Cancer Treat Rep; 1981; 65(5-6):439-41. PubMed ID: 7237464
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-performance liquid chromatographic determination of pyrazoloacridine, a nitro-9-methoxyacridine anticancer agent, in human plasma.
    Jayewardene AL; Santoro JE; Gambertoglio JG
    J Chromatogr B Biomed Sci Appl; 1997 Nov; 702(1-2):203-10. PubMed ID: 9449572
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.
    Propper DJ; de Bono J; Saleem A; Ellard S; Flanagan E; Paul J; Ganesan TS; Talbot DC; Aboagye EO; Price P; Harris AL; Twelves C
    J Clin Oncol; 2003 Jan; 21(2):203-10. PubMed ID: 12525511
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
    Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    McCrystal MR; Evans BD; Harvey VJ; Thompson PI; Porter DJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 44(1):39-44. PubMed ID: 10367747
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
    Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V
    Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical toxic effects of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY) with relevant pharmacokinetic parameters.
    Neidhart JA; Staubus AE; Young D; King GW; Malspeis L
    Cancer Treat Rep; 1980; 64(2-3):251-5. PubMed ID: 7407759
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
    Weiss GR; Kuhn JG; Rizzo J; Smith LS; Rodriguez GI; Eckardt JR; Burris HA; Fields S; VanDenBerg K; von Hoff DD
    Cancer Chemother Pharmacol; 1995; 35(5):397-402. PubMed ID: 7850921
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.
    Rischin D; Bibby DC; Chong G; Kremmidiotis G; Leske AF; Matthews CA; Wong SS; Rosen MA; Desai J
    Clin Cancer Res; 2011 Aug; 17(15):5152-60. PubMed ID: 21690571
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.